Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-07
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 337
- Registration Number
- NCT00105079
A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00104143
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT00100984
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00099177
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT00099203
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT00090766
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1228
- Registration Number
- NCT00090753
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-08-25
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 552
- Registration Number
- NCT00090051
- Locations
- 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2611
- Registration Number
- NCT00089479
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00089492
© Copyright 2024. All Rights Reserved by MedPath